Venture Kick

Unomr develops novel nano-​micro technology based sensing approaches for diagnostics and drug discovery.

Clee Medical specializes in developing innovative neuroimaging and surgical access technologies to improve precision and efficiency in neurosurgery. Their products, which include imaging and sensing systems, provide enhanced access, vision, and navigation within the brain, seamlessly integrating with existing neurosurgical equipment and current surgical routines. This enables healthcare providers to potentially enhance patient outcomes with greater precision.

Scanvio offers AI-augmented ultrasound software for faster endometriosis diagnosis, providing expert sonography skills to gynecologists, improving health and surgical education.

TrueYouOmics specializes in comprehensive blood testing services, leveraging multi-omics and artificial intelligence to identify disease risks and facilitate preventive health planning. The company's innovative approach involves analyzing an individual's DNA, RNA, and protein data, then integrating these insights with medical knowledge graphs to estimate personalized disease risks. This holistic health assessment empowers individuals to proactively manage their well-being by taking preventive measures.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

HeroSupport is a medical device manufacturing company founded in 2019 and based in Veyrier, Geneva. The company specializes in creating medical immobilization devices designed to enhance patient comfort during clinical procedures. Its innovative technology transforms imaging and treatment tables into personalized support solutions, specifically catering to the needs of patients undergoing prone breast radiotherapy. This approach allows patients to benefit from tailored support, eliminating the need for them to adjust to the standard table. By improving patient comfort, HeroSupport enables healthcare providers to deliver more effective and cost-efficient cancer treatment.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

Sensawear is a medical technology company that specializes in the production of wearable, textile-integrated sensors. These sensors monitor tissue oxygenation and skin pressure in real-time, alerting users to potential pressure injuries before they occur. By providing early warnings of low-oxygenation conditions caused by high-pressure points, Sensawear's products enable users to take preventative action, such as moving or being moved, thus minimizing the risk of painful and dangerous pressure ulcers.

SightIn Health is a company that specializes in the development of artificial intelligence-powered software designed for portable ultrasound applications. Founded in 2021 and based in Geneva, Switzerland, the company focuses on enhancing the capabilities of ultrasound machines by providing advanced image analytics, usage guidance, and interpretation of patient diagnostics. Its platform automates quality assessment and ultrasound probe guidance, effectively lowering the skill barrier required for healthcare professionals to operate ultrasound equipment. By streamlining the process of capturing and interpreting medical imaging, SightIn Health aims to improve the accuracy of medical diagnostics and prognostics in healthcare settings.

Maven Health is a health technology company that provides an innovative metabolic health solution aimed at healthcare providers. The company employs saliva as the bio-fluid for analyzing metabolites through advanced Nuclear Magnetic Resonance (NMR) spectrometry, utilizing proprietary analytical methods. This approach allows for a comprehensive assessment of individuals' metabolic health with minimal invasiveness and at a competitive cost. By delivering results via an intuitive data platform, Maven Health enables healthcare professionals to effectively identify individuals at risk for metabolic disorders who may not be detected through conventional healthcare practices.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

YLAH is a technology company specializing in the development of web and mobile solutions for psychotherapists and their patients. Its core offerings include individualized therapy tools, clinical assessment platforms, and health monitoring systems, empowering therapists to efficiently scale their services using digital means.

Avelo is a manufacturer of breath aerosol diagnostic equipment focused on providing rapid testing solutions for infectious diseases. The company has developed a non-invasive sample-to-answer breath test that reliably detects multiple lower respiratory tract infections within minutes. This process involves three simple steps, allowing healthcare providers to make timely and informed decisions regarding antibiotic or antiviral treatments. Avelo's innovative approach aims to enhance the speed and accuracy of diagnoses in primary care settings, ultimately contributing to improved patient outcomes and the potential to save lives through early intervention.

NexMR is a Swiss company specializing in nuclear magnetic resonance (NMR) technology to enhance drug discovery processes. It provides key-in-hand solutions that optimize resource use and increase throughput within drug discovery pipelines. The company's platform accelerates screening processes by integrating machine learning for data analysis, enabling efficient exploration of uncharted target spaces. NexMR's proprietary NMR techniques allow for the rapid screening of extensive libraries of molecules, streamlining the evaluation of new compounds and improving the turnaround time for experimental results. Additionally, its technology serves quality control purposes, assisting researchers in determining the content, purity, and molecular structure of chemical samples, which aids healthcare professionals in assessing the viability of potential new drugs.

NexMR is a Swiss company specializing in nuclear magnetic resonance (NMR) technology to enhance drug discovery processes. It provides key-in-hand solutions that optimize resource use and increase throughput within drug discovery pipelines. The company's platform accelerates screening processes by integrating machine learning for data analysis, enabling efficient exploration of uncharted target spaces. NexMR's proprietary NMR techniques allow for the rapid screening of extensive libraries of molecules, streamlining the evaluation of new compounds and improving the turnaround time for experimental results. Additionally, its technology serves quality control purposes, assisting researchers in determining the content, purity, and molecular structure of chemical samples, which aids healthcare professionals in assessing the viability of potential new drugs.

Sensemodi is a developer of an AI-powered smart wearable device that specializes in assessing joint health, particularly focusing on the knee and other joints. The device utilizes a combination of thermal, acoustic, and kinematic data through multiple sensor modalities to provide a quick and comprehensive evaluation of joint conditions. By facilitating easy monitoring and assessment of joint health, Sensemodi aims to prevent disability and alleviate the socioeconomic burden associated with musculoskeletal disorders. This technology empowers patients to track their joint health conveniently, ultimately leading to improved healthcare outcomes.

Oncobit is a company dedicated to enhancing personalized cancer care through the development of precise and highly sensitive diagnostic and monitoring tests. By leveraging a unique combination of technical expertise, proprietary software, and strong clinical collaborations, Oncobit aims to improve patient outcomes in cancer treatment. Initially focusing on melanoma, the company's solutions are designed to be adaptable for other cancer types in the future. Oncobit's innovations are intended to ensure that personalized therapies and diagnostics align with the evolving needs of clinics, providing essential information that enables healthcare providers to improve patient care and outcomes through more comprehensive and sensitive testing methods.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Nemosia is a company focused on the development of positron emission tomography (PET) tracers aimed at diagnosing neurological disorders. Utilizing advanced technology, Nemosia creates tracers that facilitate the early detection of neurodegenerative diseases by visualizing N-methyl-D-aspartate (NMDA) receptors in the brain. This innovative approach allows for timely intervention, enabling patients to take proactive measures against neurological conditions. Through its specialized PET imaging capabilities, Nemosia contributes to improved diagnostic accuracy and better patient outcomes in the field of neurology.

ArcoScreen is a Swiss medtech company focused on advancing drug discovery through its innovative microfluidic platform. This platform specializes in drug screening that targets cell membrane receptors, offering a faster and more efficient method for conducting chip-based GPCR assays. By enabling the identification of a drug's mode of action directly on patient cells, ArcoScreen's technology allows for the simultaneous testing of proteins that make up the drugs, assessing their efficacy in a single test. This approach aims to facilitate the treatment of complex diseases such as cancer, Alzheimer's, and diabetes, ultimately enhancing the drug development process for researchers.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Neurosoft Bioelectronics is a Swiss company specializing in the development of soft implantable electrodes designed for interfacing with the nervous system. The company focuses on creating advanced neural implants that can record and stimulate the brain, spinal cord, and peripheral nerves, addressing the limitations of traditional stiff devices that hinder patient outcomes. Its flagship product, the SOFT ECoG, is a subdural electrode that facilitates effective brain monitoring and stimulation while minimizing electrical resistance and MRI artifacts. This innovative technology aims to achieve long-term bio-integration with neural tissues, adapting to both static and dynamic mechanical properties, which enhances therapeutic capabilities for patients suffering from neurological disorders. Ultimately, Neurosoft Bioelectronics strives to improve clinical outcomes and expand the potential applications of neural interfaces in healthcare.

Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.

4iLabs is developing a diagnostic toolbox to support clinicians in the therapy decision-making process for patients with progressed cancer beyond the standard of care.

peakPCR develops Polymerase Chain Reaction (PCR) devices for research and private laboratories. peakPCR is a low-cost, small size device capable of performing real-time polymerase chain reaction (qPCR). PCR is a method widely used in molecular biology to duplicate DNA segments, with applications such as genotyping, mutation detection, forensics, and paternity testing. The Polymerase Chain Reaction (PCR) is a widely used molecular technique to make millions of copies of a DNA sample, with applications in a variety of fields such as medical diagnostics, biotechnology, and forensic sciences. We have analyzed the heat transfer limitations of conventional PCR machines. This has led to the design of a completely new sample holder with extremely high heating and cooling rates and a much lower sample volume, in order to cut analysis time from currently 1-2 h down to 10 minutes, and reagent consumption by 90%. Next to a first stand-alone desktop instrument, we have also developed a portable version that is battery-powered and that operates in conjunction with a smartphone. We aim to deploy these PCR devices to research and private laboratories at affordable prices.

Emovo Care SA is a medical device company based in Lausanne, Switzerland, founded in 2020. It specializes in developing accessible robotic devices aimed at assisting individuals with hand motor impairments, particularly those recovering from stroke. The company's flagship product is an active orthosis designed for hemiparetic stroke patients, allowing them to practice hand movements in the comfort of their homes. Emovo's orthosis utilizes innovative technology initially developed during doctoral research at EPFL, which garnered significant attention for its advancements in brain-computer interfaces. The device is complemented by a mobile application that tracks usage and motivates patients, enhancing engagement for individuals, clinicians, and health insurance providers alike, thereby aiming to improve overall care outcomes. Emovo Care SA holds ISO 13485 certification, underscoring its commitment to quality in the medical device sector.

Nutrix is a Swiss health-tech company based in Basel, founded in 2019, that specializes in developing innovative healthcare solutions. The company's flagship product is a nanosensor that is placed on the tooth to measure glucose levels in saliva, which communicates data to an external application. This technology not only tracks food intake but also offers dietary recommendations to help prevent diabetes. Nutrix aims to enhance health monitoring through precision medicine by combining advanced AI with wearables and digital coaching. In 2025, the company plans to launch CortiSense, a non-invasive cortisol monitoring sensor, further expanding its range of health monitoring solutions. By providing cost-effective and user-friendly tools, Nutrix seeks to empower individuals to manage their health proactively, reducing the need for frequent medical consultations.

epyMetrics AG is a Swiss health analytics company specializing in diagnostic wearable solutions designed to monitor the body's heat balance. Established in 2019 and based in Zurich, the company offers a comprehensive wearable device that enables users to continuously and non-invasively track their thermoregulation. This technology is specifically aimed at detecting early signs of heat stress and preventing heat-related accidents, making it particularly beneficial for various industries. The wearable not only measures vital signs but also assesses sweat rate and total sweat loss, providing critical insights into hydration levels and enabling personalized safety benchmarks tailored to different sectors. Through its innovative approach, epyMetrics aims to enhance health safety and reduce costs associated with heat-related incidents.

MimiX Biotherapeutics Sàrl is a Swiss company founded in 2016 that specializes in biofabrication technology focused on tissue manufacturing for therapeutic and diagnostic applications. Based in La Tène, the company aims to revolutionize regenerative and personalized medicine through its innovative point-of-care approach. By developing ultra-fast biomanufacturing technology, MimiX Biotherapeutics seeks to create patient-specific biological tissue equivalents, facilitating tailored treatments that meet individual medical needs.

EarlySight SA is a Swiss medical device company established in 2016 and headquartered in Lausanne. It specializes in developing advanced imaging technology to aid in the early detection and treatment of eye diseases. The company's innovative eye fundus camera utilizes cellular-level imaging and transscleral illumination to provide detailed images of the retina, allowing for the detection of minor structural changes. This technology enables eye specialists to monitor treatment effects rapidly and non-invasively, enhancing their ability to visualize the morphology of retinal cells. EarlySight aims to bring its cutting-edge solutions to clinics, thereby improving patient outcomes in ophthalmology.

Selph is a medical technology company that focuses on developing a medical device that enables people to conduct a self-test for sexually transmitted diseases. It specializes in digital health, sensors, diagnostics, and medical services.

OptiChroniX is a Swiss-based digital health solutions company focused on enhancing brain health through early intervention. The company specializes in developing digital therapeutics that integrate biomedical, behavioral, computing, and engineering research. These interventions are deployed on smartphones and utilize data from wearable devices to personalize and monitor patients' health progress. OptiChroniX aims to improve clinical outcomes, quality of life, and cost-effectiveness by providing tailored coaching to enhance health literacy, medication adherence, and address modifiable risk factors associated with cognitive decline in conditions like Alzheimer’s disease and related comorbidities.

Testmate Health is a medtech startup and an award-winning spin-off from the University of Geneva, Switzerland. The company has developed a smartphone-compatible platform that offers a test kit capable of diagnosing diseases with identifiable DNA or RNA sequences without laboratory involvement, providing rapid results at home in minutes. Their initial product is a user-friendly, all-in-one kit that serves as the first rapid urine self-test for the four most common sexually transmitted diseases (STDs). Given that one million new STDs are diagnosed daily, Testmate Health addresses a critical gap in the market, as traditional testing often requires lab processing and can take up to a week for results. The kit not only delivers immediate results but also allows users to scan their results with a smartphone, facilitating quick access to treatment if necessary. Additionally, Testmate Health has plans to expand its offerings with test kits for other diseases, empowering individuals to manage their health conveniently from home.

Neurosoft Bioelectronics is a Swiss company specializing in the development of soft implantable electrodes designed for interfacing with the nervous system. The company focuses on creating advanced neural implants that can record and stimulate the brain, spinal cord, and peripheral nerves, addressing the limitations of traditional stiff devices that hinder patient outcomes. Its flagship product, the SOFT ECoG, is a subdural electrode that facilitates effective brain monitoring and stimulation while minimizing electrical resistance and MRI artifacts. This innovative technology aims to achieve long-term bio-integration with neural tissues, adapting to both static and dynamic mechanical properties, which enhances therapeutic capabilities for patients suffering from neurological disorders. Ultimately, Neurosoft Bioelectronics strives to improve clinical outcomes and expand the potential applications of neural interfaces in healthcare.

Swiss Medical Union SA is a healthcare technology company based in Yverdon-les-Bains, Switzerland, founded in 2019. The company specializes in the manufacture of Micro-Bioreactors, which are used to test the interaction, efficiency, and safety of new medical products using models of human organs and tissues. This innovative equipment enables the selection of appropriate therapies ex vivo tailored to individual patient needs. In addition to its bioreactor technology, Swiss Medical Union develops software that simulates the activity of multiple organs, facilitating real-time analysis of interactions between active products and specific human organs. This technology allows monitoring of the effects of injected products within the circulatory system. The company also offers clinical testing services to hospitals, healthcare institutions, government clients, and international clinical facilities, supporting medical professionals in making informed decisions, particularly in cancer treatment.

Autonomyo is a Swiss company founded in 2014, based in Lausanne, that specializes in developing robotic rehabilitation solutions for individuals with neurological gait disorders. The company focuses on manufacturing a lightweight exoskeleton designed to facilitate robotically assisted gait training, which can be utilized in rehabilitation clinics as well as in home settings with remote monitoring capabilities. Autonomyo's team, comprised of engineers, developers, and healthcare professionals, is dedicated to enhancing accessibility and training intensity for people with neuromuscular and motor disorders, ultimately aiming to improve their mobility and restore their freedom of movement.

C-MedTec is a company focused on enhancing the detection and monitoring of brain concussions through innovative technology. It has developed a specialized helmet that serves as a medical imaging modality capable of measuring brain metabolism and identifying abnormal neurological behavior following a traumatic impact. This advancement addresses the significant gap in concussion diagnosis, which traditionally relies on subjective assessments by trained professionals. By providing early detection and diagnosis, C-MedTec aims to promote safer sports practices and mitigate the risk of long-term effects and chronic conditions such as Alzheimer's disease and chronic traumatic encephalopathy (CTE). Through its cutting-edge approach, the company seeks to improve health outcomes for athletes and individuals at risk of brain trauma.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.

Frater.swiss is engaged in the development and production of innovative devices and applications designed for out-of-hospital care, with a particular focus on hypothermic patients. The company creates products that assist healthcare professionals in high-stress environments, including emergency medicine, military medicine, expedition medicine, and veterinary medicine. Their offerings provide efficient measures for assessing hypothermia and stabilizing patient temperature through warm infusion, thereby enhancing the quality of medical care available in critical situations. Frater.swiss aims to empower medical personnel to effectively save lives outside traditional hospital settings.

4i Labs generates multiplexed images of biological samples for molecular view of tumours.

Frater.swiss is engaged in the development and production of innovative devices and applications designed for out-of-hospital care, with a particular focus on hypothermic patients. The company creates products that assist healthcare professionals in high-stress environments, including emergency medicine, military medicine, expedition medicine, and veterinary medicine. Their offerings provide efficient measures for assessing hypothermia and stabilizing patient temperature through warm infusion, thereby enhancing the quality of medical care available in critical situations. Frater.swiss aims to empower medical personnel to effectively save lives outside traditional hospital settings.

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of innovative healthcare devices. The company has created EmbryoSpin, a device that performs microscopic Nuclear Magnetic Resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold. This groundbreaking device is designed to operate at the scale of a single human embryo, providing a robust and user-friendly solution for researchers. EmbryoSpin facilitates non-invasive embryo viability screening for in-vitro fertilization and enhances biochemical research by allowing detailed chemical analysis of microscopic samples. Annaida Technologies' advancements aim to improve outcomes in reproductive health and deepen understanding in various areas of biochemical research.

ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.

B-rayZ is a company that originated as a spin-off from the University Hospital Zurich, focusing on the intersection of artificial intelligence and medical imaging. Comprising a team of professional radiologists, data scientists, and physicians with extensive experience in radiology, B-rayZ specializes in developing predictive deep learning analytical tools and algorithms. Their software is designed to assist radiologists specifically in the area of mammography, providing real-time assessments of image quality and breast density. This technology facilitates accurate and standardized evaluations of medical imaging data, ultimately enhancing breast cancer detectability. By equipping specialists with intelligent tools, B-rayZ aims to improve the detection of breast cancer while also contributing to the reduction of healthcare costs.

DIANA develops new dosimeters for radio diagnostic applications (especially interventional radiology) based on technology developed for high energy physics experiments

Frater.swiss is engaged in the development and production of innovative devices and applications designed for out-of-hospital care, with a particular focus on hypothermic patients. The company creates products that assist healthcare professionals in high-stress environments, including emergency medicine, military medicine, expedition medicine, and veterinary medicine. Their offerings provide efficient measures for assessing hypothermia and stabilizing patient temperature through warm infusion, thereby enhancing the quality of medical care available in critical situations. Frater.swiss aims to empower medical personnel to effectively save lives outside traditional hospital settings.

Positrigo AG is a Zurich-based company specializing in the development, manufacturing, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on providing functional imaging solutions that facilitate the early detection of neurodegenerative diseases, particularly Alzheimer's disease, as well as other conditions like Lewy body dementia, vascular dementia, and frontotemporal dementia. The company's PET scanners are designed to be accessible and affordable, enabling healthcare professionals to diagnose and monitor treatment effectively, while also contributing to the advancement of new therapies in the field of neurology.

ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.

MOMM Diagnostics is a Swiss company based in Basel, established in 2018, that specializes in the development of innovative diagnostic devices for the early diagnosis of preeclampsia, a serious condition affecting pregnant women. The company focuses on creating in-vitro diagnostic tests that can be utilized at the point of care, allowing for timely detection and intervention. By providing rapid diagnostic solutions, MOMM Diagnostics aims to enhance the quality of care for expectant mothers and improve health outcomes related to preeclampsia.

DIANA develops new dosimeters for radio diagnostic applications (especially interventional radiology) based on technology developed for high energy physics experiments

EBAMed SA is a Swiss startup based in Geneva that specializes in developing innovative medical devices for the non-invasive treatment of heart arrhythmias. Founded in 2018, the company focuses on creating an ultrasound-based device that utilizes proton therapy to monitor heart motion and synchronize therapeutic beams in real time. This technology allows for the precise delivery of radiation treatment to targeted heart tissues, thereby expanding treatment options for existing proton therapy centers and enabling them to treat heart patients effectively. By providing a non-invasive approach to cardiac care, EBAMed aims to improve patient outcomes and streamline treatment processes in outpatient settings.

Clemedi AG is a Swiss-based company founded in 2018 that specializes in developing diagnostic workflows for infectious diseases. The company creates in vitro diagnostic tests by integrating next-generation sequencing and machine learning technologies. These innovative tests are designed to diagnose drug-resistant infections directly from patient samples within a single day, supporting timely and personalized antibiotic therapy. By providing healthcare professionals with critical information, Clemedi aims to enhance decision-making in the treatment of infectious diseases, ultimately contributing to the fight against antibiotic resistance. This approach is particularly significant given projections that antibiotic-resistant bacteria could lead to 10 million deaths annually by 2050.

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of innovative healthcare devices. The company has created EmbryoSpin, a device that performs microscopic Nuclear Magnetic Resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold. This groundbreaking device is designed to operate at the scale of a single human embryo, providing a robust and user-friendly solution for researchers. EmbryoSpin facilitates non-invasive embryo viability screening for in-vitro fertilization and enhances biochemical research by allowing detailed chemical analysis of microscopic samples. Annaida Technologies' advancements aim to improve outcomes in reproductive health and deepen understanding in various areas of biochemical research.

Positrigo AG is a Zurich-based company specializing in the development, manufacturing, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on providing functional imaging solutions that facilitate the early detection of neurodegenerative diseases, particularly Alzheimer's disease, as well as other conditions like Lewy body dementia, vascular dementia, and frontotemporal dementia. The company's PET scanners are designed to be accessible and affordable, enabling healthcare professionals to diagnose and monitor treatment effectively, while also contributing to the advancement of new therapies in the field of neurology.

DocsVisit is a healthcare management platform that facilitates connections between patients and medical practitioners for home visits. By leveraging machine learning, artificial intelligence, and advanced search algorithms, the platform tracks locally available caregivers and enables patients to easily find and book appointments for medical checkups at home. This innovative approach streamlines the process of accessing private medical care, allowing patients to connect with qualified doctors and physicians who offer home visit services.

Mirrakoi SA is a Swiss company specializing in the development of computer-aided design software, particularly for the medical field. Founded in 2018 as a spin-off from the Swiss Federal Institute of Technology in Lausanne, Mirrakoi offers an innovative solution known as Rhino3DMedical. This proprietary software facilitates a streamlined workflow that allows users to view, analyze, and segment medical images, ultimately creating 3D-printable anatomical models from CT and MRI scans. The technology is designed for orthopedic surgical planning, enabling the development of patient-specific models with ease through an intuitive interface and guided workflow. Mirrakoi's focus on enhancing the design process in the medical sector positions it as a leader in augmented design technology.

EBAMed SA is a Swiss startup based in Geneva that specializes in developing innovative medical devices for the non-invasive treatment of heart arrhythmias. Founded in 2018, the company focuses on creating an ultrasound-based device that utilizes proton therapy to monitor heart motion and synchronize therapeutic beams in real time. This technology allows for the precise delivery of radiation treatment to targeted heart tissues, thereby expanding treatment options for existing proton therapy centers and enabling them to treat heart patients effectively. By providing a non-invasive approach to cardiac care, EBAMed aims to improve patient outcomes and streamline treatment processes in outpatient settings.

Positrigo AG is a Zurich-based company specializing in the development, manufacturing, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on providing functional imaging solutions that facilitate the early detection of neurodegenerative diseases, particularly Alzheimer's disease, as well as other conditions like Lewy body dementia, vascular dementia, and frontotemporal dementia. The company's PET scanners are designed to be accessible and affordable, enabling healthcare professionals to diagnose and monitor treatment effectively, while also contributing to the advancement of new therapies in the field of neurology.

IDUN Technologies AG, established in 2017 and based in Opfikon, Switzerland, specializes in designing and manufacturing biosensors for wearable devices. The company's primary product is DRYODES, a line of dry conductive electrodes used for bio-potential monitoring, including ECG, EEG, and EMG applications. IDUN's innovative bioinspired surfaces enable natural adhesion without adhesives or stickers, making its products suitable for consumer applications and brain-computer interfaces. The company's vision is to use in-ear EEGs to create a more connected world by providing real-time neuro marker measurements through its Guardian Neuro-Intelligence Platform. IDUN integrates neuroscience into everyday product designs, enabling connected devices to understand users' emotional needs better, thereby enhancing product experiences.

Clemedi AG is a Swiss-based company founded in 2018 that specializes in developing diagnostic workflows for infectious diseases. The company creates in vitro diagnostic tests by integrating next-generation sequencing and machine learning technologies. These innovative tests are designed to diagnose drug-resistant infections directly from patient samples within a single day, supporting timely and personalized antibiotic therapy. By providing healthcare professionals with critical information, Clemedi aims to enhance decision-making in the treatment of infectious diseases, ultimately contributing to the fight against antibiotic resistance. This approach is particularly significant given projections that antibiotic-resistant bacteria could lead to 10 million deaths annually by 2050.

DocsVisit is a healthcare management platform that facilitates connections between patients and medical practitioners for home visits. By leveraging machine learning, artificial intelligence, and advanced search algorithms, the platform tracks locally available caregivers and enables patients to easily find and book appointments for medical checkups at home. This innovative approach streamlines the process of accessing private medical care, allowing patients to connect with qualified doctors and physicians who offer home visit services.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

EBAMed SA is a Swiss startup based in Geneva that specializes in developing innovative medical devices for the non-invasive treatment of heart arrhythmias. Founded in 2018, the company focuses on creating an ultrasound-based device that utilizes proton therapy to monitor heart motion and synchronize therapeutic beams in real time. This technology allows for the precise delivery of radiation treatment to targeted heart tissues, thereby expanding treatment options for existing proton therapy centers and enabling them to treat heart patients effectively. By providing a non-invasive approach to cardiac care, EBAMed aims to improve patient outcomes and streamline treatment processes in outpatient settings.

Dicronis GmbH, founded in 2018 and based in Monteggio, Switzerland, specializes in the development of innovative microneedle technology for diagnostic and therapeutic applications. The company's flagship product, Lymphit, is a wearable device designed to monitor lymphatic function in a safe and scalable manner from the patient's home. This device allows for the early diagnosis of secondary lymphedema, a significant complication that can arise from cancer treatments. By utilizing a wearable patch that applies a fluorescent substance to the skin, Lymphit measures its uptake into lymph vessels through a portable detector. This real-time monitoring enables healthcare providers to diagnose lymphedema before symptoms develop and to tailor conservative treatment strategies effectively. As a result, Dicronis aims to improve patient outcomes and quality of life while also generating cost savings for the healthcare system.

Mirrakoi SA is a Swiss company specializing in the development of computer-aided design software, particularly for the medical field. Founded in 2018 as a spin-off from the Swiss Federal Institute of Technology in Lausanne, Mirrakoi offers an innovative solution known as Rhino3DMedical. This proprietary software facilitates a streamlined workflow that allows users to view, analyze, and segment medical images, ultimately creating 3D-printable anatomical models from CT and MRI scans. The technology is designed for orthopedic surgical planning, enabling the development of patient-specific models with ease through an intuitive interface and guided workflow. Mirrakoi's focus on enhancing the design process in the medical sector positions it as a leader in augmented design technology.

IDUN Technologies AG, established in 2017 and based in Opfikon, Switzerland, specializes in designing and manufacturing biosensors for wearable devices. The company's primary product is DRYODES, a line of dry conductive electrodes used for bio-potential monitoring, including ECG, EEG, and EMG applications. IDUN's innovative bioinspired surfaces enable natural adhesion without adhesives or stickers, making its products suitable for consumer applications and brain-computer interfaces. The company's vision is to use in-ear EEGs to create a more connected world by providing real-time neuro marker measurements through its Guardian Neuro-Intelligence Platform. IDUN integrates neuroscience into everyday product designs, enabling connected devices to understand users' emotional needs better, thereby enhancing product experiences.

ReflectUS develops a new diagnostic device for breast cancer diagnosis based on innovations in ultrasound imaging.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

Mirrakoi SA is a Swiss company specializing in the development of computer-aided design software, particularly for the medical field. Founded in 2018 as a spin-off from the Swiss Federal Institute of Technology in Lausanne, Mirrakoi offers an innovative solution known as Rhino3DMedical. This proprietary software facilitates a streamlined workflow that allows users to view, analyze, and segment medical images, ultimately creating 3D-printable anatomical models from CT and MRI scans. The technology is designed for orthopedic surgical planning, enabling the development of patient-specific models with ease through an intuitive interface and guided workflow. Mirrakoi's focus on enhancing the design process in the medical sector positions it as a leader in augmented design technology.

Certus Molecular Diagnostics AG specializes in the development and provision of molecular rapid tests designed for the on-site detection of mycoplasma contamination in cell cultures, as well as the identification of specific genes in various microorganisms. Founded in 2007 and headquartered in Bern, Switzerland, the company aims to enhance the reliability and efficiency of microbial testing in laboratory settings. By focusing on rapid diagnostics, Certus Molecular Diagnostics addresses critical needs in research and clinical environments, offering solutions that facilitate timely decision-making and quality control in cell culture processes. The company serves both domestic and international markets, contributing to advancements in molecular diagnostics.

IDUN Technologies AG, established in 2017 and based in Opfikon, Switzerland, specializes in designing and manufacturing biosensors for wearable devices. The company's primary product is DRYODES, a line of dry conductive electrodes used for bio-potential monitoring, including ECG, EEG, and EMG applications. IDUN's innovative bioinspired surfaces enable natural adhesion without adhesives or stickers, making its products suitable for consumer applications and brain-computer interfaces. The company's vision is to use in-ear EEGs to create a more connected world by providing real-time neuro marker measurements through its Guardian Neuro-Intelligence Platform. IDUN integrates neuroscience into everyday product designs, enabling connected devices to understand users' emotional needs better, thereby enhancing product experiences.

Dicronis GmbH, founded in 2018 and based in Monteggio, Switzerland, specializes in the development of innovative microneedle technology for diagnostic and therapeutic applications. The company's flagship product, Lymphit, is a wearable device designed to monitor lymphatic function in a safe and scalable manner from the patient's home. This device allows for the early diagnosis of secondary lymphedema, a significant complication that can arise from cancer treatments. By utilizing a wearable patch that applies a fluorescent substance to the skin, Lymphit measures its uptake into lymph vessels through a portable detector. This real-time monitoring enables healthcare providers to diagnose lymphedema before symptoms develop and to tailor conservative treatment strategies effectively. As a result, Dicronis aims to improve patient outcomes and quality of life while also generating cost savings for the healthcare system.

MesenFlow Technologies specializes in innovative bio-imaging technology aimed at enhancing drug and cosmetic development. The company’s platform addresses critical challenges in modern drug development, including species cross-reactivity and the ethical concerns of animal testing. By utilizing proprietary protocols on primary human cells, MesenFlow enables early definition of a drug's mechanism of action and its relevance to human biology. This approach not only accelerates the pharmaceutical testing process but also extends to the cosmetics and nutraceutical sectors, allowing for the assessment of product safety and efficacy at an early stage. MesenFlow's technology is particularly beneficial for organizations requiring animal-free testing solutions, ensuring compliance with regulatory demands while prioritizing human biological impact.

ReflectUS develops a new diagnostic device for breast cancer diagnosis based on innovations in ultrasound imaging.

Komed Health is a developer of a secure messaging platform specifically designed for healthcare professionals, facilitating instant communication among medical teams. The application streamlines and organizes real-time interactions, rendering traditional in-hospital communication methods such as fixed phones, pagers, and emails increasingly obsolete. It integrates seamlessly with existing clinical systems, allowing healthcare providers to access and share critical medical information for effective decision-making at the point of care. By collaborating closely with healthcare providers, Komed Health aims to enhance its platform with advanced features tailored to the needs of modern healthcare workflows, ultimately improving care delivery through intelligent communication.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

Dicronis GmbH, founded in 2018 and based in Monteggio, Switzerland, specializes in the development of innovative microneedle technology for diagnostic and therapeutic applications. The company's flagship product, Lymphit, is a wearable device designed to monitor lymphatic function in a safe and scalable manner from the patient's home. This device allows for the early diagnosis of secondary lymphedema, a significant complication that can arise from cancer treatments. By utilizing a wearable patch that applies a fluorescent substance to the skin, Lymphit measures its uptake into lymph vessels through a portable detector. This real-time monitoring enables healthcare providers to diagnose lymphedema before symptoms develop and to tailor conservative treatment strategies effectively. As a result, Dicronis aims to improve patient outcomes and quality of life while also generating cost savings for the healthcare system.

Sleepiz AG, founded in 2018 and headquartered in Zurich, Switzerland, specializes in manufacturing a non-contact sleep disorder-screening device. The product monitors breathing, heart rate, and body movements with medical-grade accuracy using wireless millimeter wave technology, sensor fusion, and artificial intelligence. This device is designed to be placed on the bedside table for easy use, enabling healthcare professionals to monitor patients' sleep patterns from home. Sleepiz aims to facilitate long-term monitoring of chronic diseases, allowing for faster intervention and improved treatment outcomes.

Komed Health is a developer of a secure messaging platform specifically designed for healthcare professionals, facilitating instant communication among medical teams. The application streamlines and organizes real-time interactions, rendering traditional in-hospital communication methods such as fixed phones, pagers, and emails increasingly obsolete. It integrates seamlessly with existing clinical systems, allowing healthcare providers to access and share critical medical information for effective decision-making at the point of care. By collaborating closely with healthcare providers, Komed Health aims to enhance its platform with advanced features tailored to the needs of modern healthcare workflows, ultimately improving care delivery through intelligent communication.

Immunas develops a point-of-care diagnostic device that within minutes will be able to determine if the source of infection is bacterial or viral. This will lead to informed antibiotic treatment decisions and reduce the number of avoidable deaths in societies due to antimicrobial resistance. Immunas is a med-tech start-up aiming to develop a rapid test allowing doctors to accurately distinguish the sources of infection. The test reduces antibiotic overuse and helps minimize antibiotic resistance. Patients receive optimal treatment faster with the test. Unlike traditional procedures that take hours to days to complete, Immunas' cutting edge chip-based technology, within minutes, will be able to accurately determine whether the cause of infection is bacterial or viral. Together with cost-effectiveness, ease-of-use, minimal invasiveness for the patient and immense potential impact on pressing public health concerns, we genuinely hope to enable smart and responsible use of antibiotics for the benefits of patients and for societies at large.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.

Kinastic AG, established in 2016 and based in Winterthur, Switzerland, specializes in digital solutions for the fitness and wellness sector. The company offers a multi-industry platform designed to enhance corporate health management by connecting organizations with their communities. Its two primary products are kinastic Club and kinastic Coach. Kinastic Club enables the creation and sharing of personalized workout programs, while kinastic Coach functions as a virtual, AI-driven personal trainer that tailors individual training plans to meet users' specific health and fitness goals. This innovative approach allows companies to support their employees' health holistically through structured health programs, fostering a culture of wellness and fitness within organizations.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing microbiome therapies for gastrointestinal diseases. Established in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create treatments for conditions that disrupt the gut microbiota ecosystem, including clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome utilizes an innovative technology platform that facilitates the efficient development and production of defined, function-based microbiome therapies, enabling swift translation from research to clinical product readiness. The company's proprietary pipeline emphasizes the use of tailored, ecologically sound bacterial mixtures, distinguishing its approach from traditional fecal microbiota transplantation methods, thus offering a new standard for treating intestinal infections.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing microbiome therapies for gastrointestinal diseases. Established in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create treatments for conditions that disrupt the gut microbiota ecosystem, including clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome utilizes an innovative technology platform that facilitates the efficient development and production of defined, function-based microbiome therapies, enabling swift translation from research to clinical product readiness. The company's proprietary pipeline emphasizes the use of tailored, ecologically sound bacterial mixtures, distinguishing its approach from traditional fecal microbiota transplantation methods, thus offering a new standard for treating intestinal infections.

Inositec AG, established in 2015 and based in Zurich, Switzerland, is a biotechnology company specializing in the development of novel drugs for soft tissue calcification disorders. It leverages its proprietary Inositune platform, which involves the engineering of inositol phosphate (IP6) analogs by selectively replacing phosphate groups with other chemical groups. This tunable approach enables the creation of molecules with enhanced drug-like properties, tailored for specific therapeutic indications. Inositec's lead programs focus on vascular and renal calcification disorders, including orphan indications, aiming to provide non-antibiotic, toxin-targeted therapies for conditions such as Clostridium difficile infections.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing microbiome therapies for gastrointestinal diseases. Established in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create treatments for conditions that disrupt the gut microbiota ecosystem, including clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome utilizes an innovative technology platform that facilitates the efficient development and production of defined, function-based microbiome therapies, enabling swift translation from research to clinical product readiness. The company's proprietary pipeline emphasizes the use of tailored, ecologically sound bacterial mixtures, distinguishing its approach from traditional fecal microbiota transplantation methods, thus offering a new standard for treating intestinal infections.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.

Lucentix is a Swiss company that specializes in biosensor technology, enabling patients to measure precise concentrations of analytes using just a single drop of blood or saliva. The company’s innovative handheld device delivers laboratory-quality results at a low cost, enhancing accessibility and convenience for users. Its biosensors utilize a novel biochemical sensing molecule, engineered from a light-producing enzyme called luciferase, which alters the color of emitted light in response to changes in analyte concentration. In the absence of the analyte, the system emits red light, while higher concentrations produce blue light. This technology allows for rapid point-of-care testing, providing patients with timely and accurate health information. Lucentix is headquartered in Lausanne, Switzerland.

TheranOptics SARL is a Swiss company based in Neuchâtel, established in 2016. The firm specializes in the development of fiber-based sensor equipment designed for the chemical analysis of chronic wounds. Given the prevalence of chronic wounds affecting a segment of the Swiss population, TheranOptics aims to address this medical challenge through innovative technology that enhances the understanding and management of such conditions.

CellSpring is a biotechnology company based in Zurich, Switzerland, specializing in the development of 3D micro tissues for diverse biological applications. Its primary technology, the 3D Bloom platform, allows for the rapid creation of biomimetic microtissues that are not dependent on specific cell types. This innovative platform enhances existing 3D cell culture methods by offering improved speed, reliability, versatility, and user-friendliness. By facilitating the production of these advanced microtissues, CellSpring aims to support in vitro studies and contribute to advancements in clinical diagnostics, including the early detection of cancer.

Axiamo GmbH, founded in 2015 and based in Nidau, Switzerland, specializes in the development and manufacturing of motion sensor technology aimed at measuring key parameters of physical performance. The company offers advanced motion sensors that provide detailed data on acceleration, rotation, magnetic fields, air pressure, and temperature. These sensors enable athletes to receive objective feedback, thereby enhancing their training and performance. Additionally, Axiamo provides scientifically validated running sensors that analyze running mechanics, further supporting athletes in optimizing their performance.

SimplicityBio SA is a biotechnology company based in Monthey, Switzerland, founded in 2013 by Matthew Hall, Pedro Faustino, and Miguel Barreto. The company specializes in developing an artificial intelligence-based platform designed to analyze biological, clinical, and digital data streams, facilitating the extraction of knowledge and insights that expedite the development of biomarker signatures throughout various stages, from target identification to pre-clinical and clinical phases. Its services encompass biomarker discovery and ranking, signature creation, and the enhancement of existing signatures, catering to the molecular diagnostic market. In addition to its analytical capabilities, SimplicityBio also focuses on developing scientific innovations, intellectual property, and white paper technologies for its clients. As of March 2019, SimplicityBio operates as a subsidiary of Precision for Medicine, Inc.

Lucentix is a Swiss company that specializes in biosensor technology, enabling patients to measure precise concentrations of analytes using just a single drop of blood or saliva. The company’s innovative handheld device delivers laboratory-quality results at a low cost, enhancing accessibility and convenience for users. Its biosensors utilize a novel biochemical sensing molecule, engineered from a light-producing enzyme called luciferase, which alters the color of emitted light in response to changes in analyte concentration. In the absence of the analyte, the system emits red light, while higher concentrations produce blue light. This technology allows for rapid point-of-care testing, providing patients with timely and accurate health information. Lucentix is headquartered in Lausanne, Switzerland.

Spectroswiss Sarl is a Swiss company established in 2014 and based in Lausanne, specializing in biological mass spectrometry. It develops advanced mass analyzers and data acquisition electronics designed to enhance research in life sciences and biotechnology. The company employs proprietary methods for processing time-domain data, enabling super-resolution signal processing in Fourier transform mass spectrometry (FTMS). This innovative approach allows clients to conduct both qualitative and quantitative analyses of proteins and metabolites, facilitating vital research and applications in the life sciences sector. Spectroswiss aims to accelerate scientific discovery by providing sophisticated tools for proteomics and metabolomics analysis.

CellSpring is a biotechnology company based in Zurich, Switzerland, specializing in the development of 3D micro tissues for diverse biological applications. Its primary technology, the 3D Bloom platform, allows for the rapid creation of biomimetic microtissues that are not dependent on specific cell types. This innovative platform enhances existing 3D cell culture methods by offering improved speed, reliability, versatility, and user-friendliness. By facilitating the production of these advanced microtissues, CellSpring aims to support in vitro studies and contribute to advancements in clinical diagnostics, including the early detection of cancer.

Xsensio is a digital health company focused on addressing the critical challenge of real-time and continuous monitoring of health parameters. The company has developed an innovative Lab-on-Skin wearable device, which serves as a modular miniaturized sensing platform. This device enables the continuous and real-time analysis of biochemical information, including proteins and hormones, at the surface of the skin. By providing unprecedented access to a wide range of biochemical parameters found in sweat, such as electrolytes and metabolites, Xsensio aims to enhance patient care in a simple and minimally invasive manner. Through this technology, the company seeks to transform healthcare from a static approach to a more dynamic and responsive model.

Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.

SimplicityBio SA is a biotechnology company based in Monthey, Switzerland, founded in 2013 by Matthew Hall, Pedro Faustino, and Miguel Barreto. The company specializes in developing an artificial intelligence-based platform designed to analyze biological, clinical, and digital data streams, facilitating the extraction of knowledge and insights that expedite the development of biomarker signatures throughout various stages, from target identification to pre-clinical and clinical phases. Its services encompass biomarker discovery and ranking, signature creation, and the enhancement of existing signatures, catering to the molecular diagnostic market. In addition to its analytical capabilities, SimplicityBio also focuses on developing scientific innovations, intellectual property, and white paper technologies for its clients. As of March 2019, SimplicityBio operates as a subsidiary of Precision for Medicine, Inc.

Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.